# National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)

> **NIH NIH U24** · INDIANA UNIVERSITY INDIANAPOLIS · 2021 · $396,250

## Abstract

The US National Plan for AD (National Alzheimer's Project Act, NAPA) has the ambitious goal of
preventing and effectively treating Alzheimer’s disease (AD) by 2025 through the support of
innovative research focused on AD etiology, early detection, and therapeutics. The National
Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) is an NIA-
funded Cooperative Agreement that serves as the primary resource for sample sharing for all
NIA-funded Alzheimer’s disease and related dementias (ADRD) studies. NCRAD received a
perfect score on its recent competitive renewal. Over the next five years, NCRAD will work closely
with NIA and other national efforts in ADRD research to advance genomic and biomarker efforts
aimed at identifying those at greatest risk for ADRD and to delay and prevent ADRD.
With the rapid development of blood-based biomarkers, there is an urgency to have a central
laboratory in the United States that can process large numbers of samples in a standardized
manner and return the data to studies. To meet this goal, Indiana University is establishing a new
biomarker laboratory that will produce key plasma assays for samples banked at the National
Centralized Repository for Alzheimer’s Disease (NCRAD). NCRAD will limit its focus to
biomarkers that are well established and can be implemented as commercial assays. Initial
assays will be: P-tau, NfL, Aβ1-40 and Aβ1-42.
NCRAD’s approach will ensure that standardization of processes and delivery of reliable and
consistent research biomarker results can be achieved. It will also allow for longitudinal quality
monitoring and consistent delivery of results over time as well as the opportunity for cross-lab
comparability studies. There are several key advantages to centralizing the biomarker laboratory
at NCRAD. First, since NCRAD banks samples from 45 studies, integrating the biomarker
laboratory within NCRAD is a seamless process to return assay data to the contributing study.
Second, studies without a biomarker focus can easily partner with NCRAD to include plasma
biomarkers with minimal effort.

## Key facts

- **NIH application ID:** 10416201
- **Project number:** 3U24AG021886-20S1
- **Recipient organization:** INDIANA UNIVERSITY INDIANAPOLIS
- **Principal Investigator:** TATIANA M. FOROUD
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $396,250
- **Award type:** 3
- **Project period:** 2002-07-15 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10416201

## Citation

> US National Institutes of Health, RePORTER application 10416201, National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) (3U24AG021886-20S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10416201. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*